DaVita

DaVita is not an asset manager — it is an operating company publicly traded as DVA on the NYSE. The firm generates returns through direct ownership and operation of dialysis clinics rather than by investing third-party capital. Its capital allocation runs through organic clinic expansion, merger and acquisition activity targeting independent dialysis providers, and joint ventures in international markets. This structure produces operating income, not management fees or carried interest.

CEO Javier Rodriguez leads the executive team responsible for capital allocation and strategic planning. Former CEO Kent Thiry, who remains Chairman, shaped the firm's investment philosophy during more than two decades of leadership. Major strategic decisions pass through the board of directors, which includes Thiry and several independent directors with healthcare and finance backgrounds. Regional operating presidents manage clinic-level capital deployment and local acquisitions.

DaVita maintains direct operations in more than 10 countries outside the United States, with the largest presence in Brazil and Colombia through joint ventures. The firm has also entered Saudi Arabia, the United Kingdom, Germany, and China through partnerships with local healthcare operators. International investments target markets with growing end-stage renal disease populations and evolving healthcare infrastructure, typically structured as majority-controlled joint ventures rather than wholly-owned subsidiaries.

DaVita primarily acquires independent dialysis centers and small regional chains through its corporate development team. The firm targets operations in markets where it can consolidate back-office functions, leverage payer relationships, and drive clinical standardization across a geographic cluster. Acquisition targets typically operate 3-15 clinics and face administrative burden or capital constraints that make integration attractive.

DaVita structures medical director agreements and joint venture partnerships with nephrology practices under the regulatory framework of the US Anti-Kickback Statute and Stark Law. Physicians retain clinical autonomy while DaVita provides operational management, capital, and administrative infrastructure. The firm's 2025 restructuring emphasized deeper integration with physician partners through expanded leadership roles and governance participation, aiming to align incentives around patient outcomes and cost efficiency (per the firm's official communications, March 2025).

DaVita's investment focus remains concentrated on kidney care, but it extends into related areas including home dialysis technology, value-based care platforms, and transplant support services. The firm holds a stake in Strive Health, a value-based kidney care company. It has historically explored and divested non-core healthcare ventures, including the sale of DaVita Medical Group to Optum in 2019, signaling a deliberate narrowing of the investment aperture around its core dialysis competency (per the firm's official filings).

The village model distributes operational decision-making to individual clinic leaders, called facility administrators, who control staffing, local marketing, and patient experience within compliance boundaries. Regional vice presidents oversee clusters of 20-30 clinics and manage capital requests. The executive team in Denver controls payer contracting, national strategy, M&A, and financial reporting. This structure creates what the firm calls a 'teammate culture' — distinct from a top-down hospital chain and more similar to a decentralized portfolio of operating companies with shared back-office functions.